ERBB2 and breast cancer: It remains uncertain whether IT administration of trastuzumab confers any tangible benefit for patients with HER2+ BC LM compared to other approaches with respect to meaningful clinical endpoints, such as quality-of-life, progression-free survival (PFS), and overall survival (OS).